Status and phase
Conditions
Treatments
About
To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
24 participants in 2 patient groups, including a placebo group
There are currently no registered sites for this trial.
Start date
Apr 01, 2008 • 16 years ago
End date
Apr 01, 2009 • 15 years ago
Today
Jan 21, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal